Displaying 30 (all) recruiting clinical trials.
-
A Phase 1 First-in-Human Open-Label Dose Escalation Study of JNJ-61186372 a Human Bispecific EGFR and cMet Antibody in Subjects with Advanced Non-Small Cell Lung Cancer
If you have been diagnosed with advanced, metastatic, non-small cell lung cancer (NSCLC), you may qualify for this study. The main goal of this study ... -
A PHASE 1 STUDY OF PALBOCICLIB (IND#141416) A CDK 4/6 INHIBITOR IN COMBINATION WITH CHEMOTHERAPY IN CHILDREN WITH RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) OR LYMPHOBLASTIC LYMPHOMA (LL)
This study is evaluating safety and feasibility of palbociclib in combination with an established re-induction platform for children, adolescents and young adults with relapsed/refractory ... -
A Phase 1/1b Open-Label Multi-Center Study to Characterize the Safety and Tolerability of TRQ15-01 in Patients with Relapsed/Refractory Solid Tumors and Lymphomas
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics and antitumor activity of TRQ15-01 administered i.v. in patients with relapsed ... -
A PHASE Ib MULTICENTER OPEN-LABEL STUDY TO EVALUATE THE SAFETY EFFICACY AND PHARMAKOKINETICS OF RO6958688 IN COMBINATION WITH ATEZOLIZUMAB AFTER PRETREATMENT WITH OBINUTUZUMAB IN PATIENTS WITH PREVIOUSLY TREATED METASTATIC MICROSATELLITE-STABLE COLORECTAL ADENOCARCINOMA WITH HIGH CEACAM5 EXPRESSION
The purpose of this study is to explore the effects, good or bad, of cibisatamab, atezolizumab, obinutuzumab, and tocilizumab on patients with CRC. In this ... -
Phase I Dose Escalation Trial of Single Fraction Adjuvant Stereotactic Body Partial Breast irradiation (SB-PBI) For Early Stage Breast Cancer
In this study, early-stage breast cancer patients will be receiving a single fraction (radiation dose) via FDA-approved Cyberknife technology. The main goal of this study ... -
Phase 1 Study of VE800 and Nivolumab in Patients with Selected Types of Advanced or Metastatic Cancer
To evaluate the safety and tolerability of VE800 in combination with nivolumab using Common Terminology Criteria for Adverse Events (CTCAE, v. 5.0). To evaluate ... -
A Phase 1 Study of TJ011133 Administered Alone or in Combination with Pembrolizumab or Rituximab in Subjects with Relapsed/Refractory Advanced Solid Tumors and Lymphoma
The purpose of this study is to test the safety of a study drug called TJ011133 alone, and to test the safety of TJ011133 in ... -
A Phase 1b Study to Determine the Safety and Tolerability and Confirm the Dose of Canakinumab and Spartalizumab in Combination With Nab-paclitaxel and Gemcitabine for Patients with Metastatic Pancreatic Cancer
The purpose of this study is to find out the tolerable dose and how safe the administration of the combination of canakinumab and spartalizumab with ... -
A Phase 1 Parallel Open-Label Study of the Safety and Tolerability Pharmacokinetics and Antileukemic Activity of ASTX660 as a Single Agent and in Combination with ASTX727 in Subjects with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
The purpose of the study is to determine the safety of ASTX660 alone and in combination with ASTX727 in patients who have acute myeloid leukemia ... -
A Phase 1 Study of RGX-104 a Small Molecule LXR Agonist as a Single Agent and as Combination Therapy in Patients with Advanced Solid Malignancies and Lymphoma with an Expansion in Select Malignancies
The purpose of the study is to look at RGX-104 as a single agent, and separately, in combination with nivolumab, ipilimumab, docetaxel, or pembrolizumab plus ...